news

 03 Aug, 2023, 16:30 ET  CUPERTINO, Calif., Aug. 3, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, today announced that the company will report its financial results […]

 20 Jul, 2023, 08:00 ET  CUPERTINO, Calif., July 20, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) (“DURECT”), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate

 07 Jun, 2023, 06:00 ET  Topline data anticipated in Q4 2023 CUPERTINO, Calif., June 7, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and chronic liver diseases, today announced that it has completed enrollment in its Phase 2b AHFIRM clinical trial (NCT04563026) investigating larsucosterol

 May 08, 2023, 16:05 ET  – Webcast of Earnings Call Today, May 8th at 4:30 p.m. ET – Topline data from AHFIRM trial expected in 2H 2023 CUPERTINO, Calif., May 8, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2023 and provided a corporate update.

 May 01, 2023, 19:03 ET  CUPERTINO, Calif., May 1, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the market close on Monday, May 8, 2023. Monday, May 8 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free: 

 Apr 27, 2023, 17:11 ET  CUPERTINO, Calif., April 27, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader (“KOL”) event on Alcohol-Associated Hepatitis on May 16th in New York City. Topics of discussion will include the etiology and prevalence of alcohol-associated hepatitis (AH), current treatment insufficiencies and unmet

 Apr 25, 2023, 18:45 ET  CUPERTINO, Calif., April 25, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce, Managing Director, Senior Biotechnology Research Analyst, H.C Wainwright & Co., LLC at the H.C. Wainwright BioConnect Investor Conference on May

 Apr 10, 2023, 06:00 ET  Data expands upon previously reported results, including individual patient data, additional liver biomarkers, and comparisons to matching arms from a contemporaneous study Company on track to report data from ongoing Phase 2b AHFIRM trial in 2H 2023 CUPERTINO, Calif., April 10, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical

 Mar 21, 2023, 16:30 ET  CUPERTINO, Calif., March 21, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.  Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election

 Mar 09, 2023, 08:30 ET  CUPERTINO, Calif., March 9, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will participate in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the